Research project

The company has established multiple precise drug research and development pipelines targeting specific targets.

BTK (full name Bruton's tyrosine kinase), also known as Bruton's tyrosine kinase, is a key kinase in the B cell receptor (BCR) signaling pathway. It is widely expressed in different types of malignant hematological diseases and participates in the proliferation, differentiation, and apoptosis of B cells. Due to the excellent specificity of BTK small molecule inhibitors, inhibiting BTK can effectively treat malignant tumors such as non Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), as well as autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, urticaria, etc. BTK inhibitors have therefore become the most promising drugs in the market for hematological malignancies and autoimmune diseases.

探索详请

Project of Triple-Target Inhibitor for Solid Tumors

The characteristic is broad-spectrum anti-cancer with three targets, strong efficacy, and high dosage. Currently, there are no similar products on the market.

Addressing the current issue of resistance to single target drugs. The indications are non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, etc. There is currently a high demand in the domestic market, and no similar products have been launched yet.

A highly active compound has been screened out, and an international patent application has been filed and accepted.

探索详请

Project of Dual-Target Inhibitor for Solid Tumors

Double target MET and TRK mutation gene inhibitors, indications: breast, adenocarcinoma, kidney cancer, etc. The company has now screened compound ZW405, which has high inhibitory activity against c-MET kinase. Currently, there are no similar products on the market internationally.

A highly active compound has been screened out, and an international patent is currently being applied for.

探索详请

ZW-810 Solid Tumor Inhibitor Project

It is a serine/threonine protein kinase inhibitor for the treatment of various solid tumors such as triple-negative breast cancer, gastric cancer, and renal cancer. Currently, no such product has been marketed globally.

探索详请

ZW-820 Solid Tumor Inhibitor Project

It is a serine/threonine protein kinase inhibitor for the treatment of various solid tumors such as acute myeloid leukemia, breast cancer, prostate cancer, and ovarian cancer. Currently, no such product has been marketed globally.

探索详请

BTK inhibitor project
Project of Triple-Target Inhibitor for Solid Tumors
Project of Dual-Target Inhibitor for Solid Tumors
ZW-810 Solid Tumor Inhibitor Project
ZW-820 Solid Tumor Inhibitor Project

PRODUCT PIPELINE

Products R&D Preclinical Phase l Phase ll Phase Ill NDA: TM-471-1
(NHL); TM-471-1
(Chronic Spontaneous Urticaria ,CSU); TM-471-1
(Autoimmune Encephalitis, AE); TM-471-1
( Multiple Sclerosis, Ms); TM-471-1
(Membranous Nephropathy,MN); ZW-610
(Triple-Target Inhibitor ); ZW-620
(Dual-Target Inhibitor ); ZW-810
(Solid Tumor lnhibitor); ZW-820
(Solid Tumor lnhibitor)

Indications for BTK inhibitors

lymphoma

Including various subtypes of non Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

Multiple myeloma (MM)

Borderline lymphoma (MZL)

Mantle cell lymphoma (MCL)

Fahrenheit macroglobulinemia (WM)
Autoimmune system diseases

Multiple sclerosis (MS)

Primary membranous nephropathy (PMN)

Rheumatoid arthritis (RA)

Systemic lupus erythematosus (SLE)

Chronic graft-versus-host disease (cGVHD)

Urticaria (CSU), etc